 Zacks Investment Research lowered shares of Harrow Health NASDAQ:HROW from a hold rating to a sell rating in a research report sent to investors on Tuesday morning, Zacks.com reports. According to Zacks, Harrow Health Inc. owns a portfolio of healthcare businesses, including an ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds Eton Pharmaceuticals, Surface Pharmaceuticals, ... 